WGS Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of 4.04%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Delcath Systems, Inc.'s return on equity of 1.59%.

GeneDx Holdings Corp. has a consensus price target of $160.89, signalling upside risk potential of 0.32%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.31 which suggests that it could grow by 130.9%. Given that Delcath Systems, Inc. has higher upside potential than GeneDx Holdings Corp., analysts believe Delcath Systems, Inc. is more attractive than GeneDx Holdings Corp..

GeneDx Holdings Corp. has a beta of 2.025, which suggesting that the stock is 102.538% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.033%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.6M. GeneDx Holdings Corp.'s net income of -$7.6M is lower than Delcath Systems, Inc.'s net income of $830K. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,659.62x while Delcath Systems, Inc.'s PE ratio is 1,110.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 11.44x versus 4.61x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of 13.85%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Illumina, Inc.'s return on equity of 30.55%.

GeneDx Holdings Corp. has a consensus price target of $160.89, signalling upside risk potential of 0.32%. On the other hand Illumina, Inc. has an analysts' consensus of $120.11 which suggests that it could fall by -6.13%. Given that GeneDx Holdings Corp. has higher upside potential than Illumina, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Illumina, Inc..

GeneDx Holdings Corp. has a beta of 2.025, which suggesting that the stock is 102.538% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. GeneDx Holdings Corp.'s net income of -$7.6M is lower than Illumina, Inc.'s net income of $150M. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,659.62x while Illumina, Inc.'s PE ratio is 28.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 11.44x versus 4.70x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings, Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of 7.34%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Labcorp Holdings, Inc.'s return on equity of 10.25%.

GeneDx Holdings Corp. has a consensus price target of $160.89, signalling upside risk potential of 0.32%. On the other hand Labcorp Holdings, Inc. has an analysts' consensus of $299.71 which suggests that it could grow by 12.77%. Given that Labcorp Holdings, Inc. has higher upside potential than GeneDx Holdings Corp., analysts believe Labcorp Holdings, Inc. is more attractive than GeneDx Holdings Corp..

GeneDx Holdings Corp. has a beta of 2.025, which suggesting that the stock is 102.538% more volatile than S&P 500. In comparison Labcorp Holdings, Inc. has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.121%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings, Inc. offers a yield of 1.08% to investors and pays a quarterly dividend of $0.72 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Labcorp Holdings, Inc. pays out 32.58% of its earnings as a dividend. Labcorp Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are smaller than Labcorp Holdings, Inc. quarterly revenues of $3.6B. GeneDx Holdings Corp.'s net income of -$7.6M is lower than Labcorp Holdings, Inc.'s net income of $261.5M. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,659.62x while Labcorp Holdings, Inc.'s PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 11.44x versus 1.62x for Labcorp Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Star Operating Cos., Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of 14.56%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Star Operating Cos., Inc.'s return on equity of -3.67%.

GeneDx Holdings Corp. has a consensus price target of $160.89, signalling upside risk potential of 0.32%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 19.4%. Given that Star Operating Cos., Inc. has higher upside potential than GeneDx Holdings Corp., analysts believe Star Operating Cos., Inc. is more attractive than GeneDx Holdings Corp..

GeneDx Holdings Corp. has a beta of 2.025, which suggesting that the stock is 102.538% more volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.714, suggesting its more volatile than the S&P 500 by 171.399%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are larger than Star Operating Cos., Inc. quarterly revenues of $23.7M. GeneDx Holdings Corp.'s net income of -$7.6M is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,659.62x while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 11.44x versus 0.48x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.